Ginkgo Bioworks Holdings (DNA) Other Non-Current Assets (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Other Non-Current Assets of $39.5 million for Q1 2026, down 16.21% on a QoQ basis from $47.2 million in Q4 2025, and down 15.51% year-over-year from $46.8 million in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $39.5 million for Q1 2026.
- Quarterly Other Non-Current Assets fell 15.51% year-over-year to $39.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.5 million (down 15.51% YoY) and the FY2025 annual result came in at $47.2 million, down 14.76% from the prior year.
- Other Non-Current Assets was $39.5 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $47.2 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $97.9 million in Q2 2023 and bottomed at $39.5 million in Q1 2026.
- A 5-year average of $61.7 million and a median of $55.3 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 8223.17% — and 2024, when it sank 38.53%.
- Ginkgo Bioworks Holdings' Other Non-Current Assets stood at $88.7 million in 2022, then tumbled by 34.57% to $58.1 million in 2023, then slipped by 4.68% to $55.3 million in 2024, then dropped by 14.76% to $47.2 million in 2025, then retreated by 16.21% to $39.5 million in 2026.
- Business Quant data shows DNA's Other Non-Current Assets at $39.5 million in Q1 2026, $47.2 million in Q4 2025, and $46.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | 39.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.52 Mn |
| Dec 31, 2025 | 47.17 Mn |
| Sep 30, 2025 | 46.59 Mn |
| Jun 30, 2025 | 47.02 Mn |
| Mar 31, 2025 | 46.78 Mn |
| Dec 31, 2024 | 55.34 Mn |
| Sep 30, 2024 | 59.79 Mn |
| Jun 30, 2024 | 60.21 Mn |
| Mar 31, 2024 | 60.63 Mn |
| Dec 31, 2023 | 58.06 Mn |
| Sep 30, 2023 | 97.02 Mn |
| Jun 30, 2023 | 97.95 Mn |
| Mar 31, 2023 | 97.26 Mn |
| Dec 31, 2022 | 88.73 Mn |
| Sep 30, 2022 | 43.93 Mn |
| Jun 30, 2022 | 53.02 Mn |
| Mar 31, 2022 | 49.62 Mn |
| Dec 31, 2021 | 1.07 Mn |
| Sep 30, 2021 | 26.80 Mn |
| Dec 31, 2020 | 5.60 Mn |